tiprankstipranks
Trending News
More News >

Vigil Neuroscience Reports 2024 Results and Clinical Progress

Vigil Neuroscience Reports 2024 Results and Clinical Progress

Vigil Neuroscience, Inc. ( (VIGL) ) has released its Q4 earnings. Here is a breakdown of the information Vigil Neuroscience, Inc. presented to its investors.

Confident Investing Starts Here:

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases by utilizing microglia, the brain’s sentinel immune cells, to create precision-based therapies. The company recently announced its financial results for the fourth quarter and full year of 2024, alongside significant advancements in its clinical programs. Vigil reported positive Phase 1 data for VG-3927, a small molecule TREM2 agonist for Alzheimer’s Disease, and plans to initiate a Phase 2 trial in the third quarter of 2025. Additionally, the company is on track to report final analysis from the IGNITE Phase 2 trial of iluzanebart for ALSP in the second quarter of 2025, with intentions to pursue accelerated approval. Financially, Vigil ended 2024 with $97.8 million in cash and equivalents, expecting this to fund operations into 2026. R&D expenses increased due to clinical activities, while G&A expenses slightly decreased. The net loss for 2024 was $84.3 million, reflecting ongoing investment in clinical development. Looking forward, Vigil is poised for a pivotal year with upcoming trial results and potential regulatory advancements, maintaining a strong cash position to support its strategic goals.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1